Fisher Asset Management LLC Lowers Position in Prestige Consumer Healthcare Inc. $PBH

Fisher Asset Management LLC lessened its holdings in shares of Prestige Consumer Healthcare Inc. (NYSE:PBH) by 3.9% during the third quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor owned 293,709 shares of the company’s stock after selling 11,917 shares during the period. Fisher Asset Management LLC’s holdings in Prestige Consumer Healthcare were worth $18,327,000 as of its most recent SEC filing.

A number of other hedge funds and other institutional investors have also recently modified their holdings of PBH. Allspring Global Investments Holdings LLC increased its position in Prestige Consumer Healthcare by 4.6% during the 3rd quarter. Allspring Global Investments Holdings LLC now owns 1,592,375 shares of the company’s stock valued at $100,893,000 after buying an additional 70,376 shares in the last quarter. Assenagon Asset Management S.A. purchased a new stake in shares of Prestige Consumer Healthcare in the third quarter worth $1,890,000. AXQ Capital LP purchased a new stake in shares of Prestige Consumer Healthcare in the second quarter worth $694,000. Tributary Capital Management LLC increased its holdings in shares of Prestige Consumer Healthcare by 157.3% during the third quarter. Tributary Capital Management LLC now owns 379,410 shares of the company’s stock valued at $23,675,000 after acquiring an additional 231,969 shares in the last quarter. Finally, Franklin Resources Inc. raised its position in shares of Prestige Consumer Healthcare by 51.8% in the 2nd quarter. Franklin Resources Inc. now owns 33,476 shares of the company’s stock worth $2,673,000 after purchasing an additional 11,429 shares during the last quarter. 99.95% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analyst Weigh In

PBH has been the subject of a number of analyst reports. Zacks Research upgraded shares of Prestige Consumer Healthcare from a “strong sell” rating to a “hold” rating in a research note on Monday, November 10th. Weiss Ratings reissued a “hold (c)” rating on shares of Prestige Consumer Healthcare in a research report on Thursday, January 22nd. Canaccord Genuity Group decreased their price objective on shares of Prestige Consumer Healthcare from $100.00 to $88.00 and set a “buy” rating for the company in a report on Friday, November 7th. Finally, Jefferies Financial Group lowered their price objective on Prestige Consumer Healthcare from $70.00 to $66.00 and set a “hold” rating on the stock in a research report on Friday, January 30th. Three analysts have rated the stock with a Buy rating and four have issued a Hold rating to the company. According to MarketBeat.com, Prestige Consumer Healthcare has a consensus rating of “Hold” and a consensus price target of $80.60.

Insider Buying and Selling at Prestige Consumer Healthcare

In related news, VP Jeffrey Zerillo sold 1,000 shares of the business’s stock in a transaction that occurred on Wednesday, February 11th. The stock was sold at an average price of $65.93, for a total value of $65,930.00. Following the transaction, the vice president directly owned 41,048 shares of the company’s stock, valued at approximately $2,706,294.64. The trade was a 2.38% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. 1.40% of the stock is currently owned by company insiders.

Prestige Consumer Healthcare Stock Performance

PBH opened at $69.13 on Thursday. The company’s 50 day moving average is $65.65 and its 200 day moving average is $63.55. The company has a current ratio of 3.11, a quick ratio of 1.93 and a debt-to-equity ratio of 0.58. The company has a market cap of $3.27 billion, a price-to-earnings ratio of 18.29, a PEG ratio of 2.17 and a beta of 0.41. Prestige Consumer Healthcare Inc. has a 12-month low of $57.25 and a 12-month high of $90.04.

Prestige Consumer Healthcare (NYSE:PBH) last announced its earnings results on Thursday, February 5th. The company reported $1.14 EPS for the quarter, missing analysts’ consensus estimates of $1.16 by ($0.02). Prestige Consumer Healthcare had a return on equity of 12.02% and a net margin of 16.90%.The company had revenue of $283.44 million during the quarter, compared to the consensus estimate of $286.93 million. During the same period in the prior year, the business posted $1.22 earnings per share. Prestige Consumer Healthcare’s revenue for the quarter was down 2.4% compared to the same quarter last year. Prestige Consumer Healthcare has set its FY 2026 guidance at 4.540-4.540 EPS. On average, equities research analysts predict that Prestige Consumer Healthcare Inc. will post 4.5 EPS for the current year.

Prestige Consumer Healthcare Profile

Prestige Consumer Healthcare, Inc is a leading manufacturer and marketer of branded over-the-counter (OTC) healthcare products. The company focuses on developing, acquiring and commercializing a diverse portfolio of non-prescription remedies designed to address common consumer health needs, including pain relief, cold and cough, digestive health, eye care, skin care and women’s health.

Key brands in Prestige’s portfolio include Clear Eyes (eye health), Carmex (lip care), Chloraseptic (sore throat relief), Dramamine (motion sickness), Rolaids (antacid), Monistat (women’s health), BC Powder (pain relief), Little Remedies (pediatric cold and gas relief) and TheraTears (dry eye therapy).